Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

evorpacept (ALX148)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

ALX Oncology

Drug class:

CD47 inhibitor

Related drugs:

‹

›

HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials trastuzumab + ramucirumab + ALX148 Sensitive : C3	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials trastuzumab + ramucirumab + ALX148 Sensitive : C3
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials trastuzumab + ramucirumab + ALX148 Sensitive : C3	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials trastuzumab + ramucirumab + ALX148 Sensitive : C3
CD20 positive	Non-Hodgkin’s Lymphoma	CD20 positive	Non-Hodgkin’s Lymphoma	rituximab + ALX148 Sensitive: C3 – Early Trials rituximab + ALX148 Sensitive : C3	rituximab + ALX148 Sensitive: C3 – Early Trials rituximab + ALX148 Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	ALX148 Sensitive: C3 – Early Trials ALX148 Sensitive : C3	ALX148 Sensitive: C3 – Early Trials ALX148 Sensitive : C3